Speaker in Pharma Session 2 – Biosimilars – similar but different?
Monday, September 19, 2016 from 11.00 to 12.30
Fritz Reiter studied Chemistry at the University of Innsbruck, Austria and hold a Ph.D. in Biochemistry from the University of Innsbruck. He worked as University assistant for teaching and research for 4 years, focusing on tumorigenesis induced by oncogenic transcription factors.
In 2006 he joined Sandoz Biopharmaceuticals, the pioneer in biosimilar development. He held several positions within Regulatory Affairs Biopharmaceuticals, helping to shape the biosimilar landscape worldwide. As Regulatory CMC Team leader (from 2013) he has broad experience in global biosimilar development and worldwide submissions of biosimilar applications (including Omnitrope (human growth hormone), Zarzio (filgrastim) and the recently FDA approved Erelzi (etanercept)) as well in life cycle management of biosimilars.